1PhD Scholar,
2
3
*Corresponding Author E-mail: swati_pharmaco@yahoo.co.in
Ocular drug delivery is one of the most challenging and fascinating task faced by the Pharmaceutical Researchers. The challenges to the formulators are to circumvent the protective barriers of the eye without causing permanent tissue damage, maintain a stable therapeutic level at the site of action for a prolonged period of time. Frequent instillation to maintain a continuous sustained therapeutic level is required which often results in local or systemic side effects. The objective of the present investigation is to formulate a novel drug delivery system for ophthalmic use for the treatment of ocular conjunctivitis. Ocusrets of Gemifloxacin Mesylate and Dexamethasone were formulated and evaluated.
Initially preformulation studies of Gemifloxacin Mesylate, Dexamethasone, polymer and excipients were performed to check their compatibility. Different combinations of Gemifloxacin Mesylate, Dexamethasone, Carbopol 974, 980 981, PEG 400 and glycerine were formulated by solvent cast method and evaluated.
The formulated ocusert was evaluated for clarity, smoothness, surface pH, drug content, and in-vitro drug release study.
Formula GD 74 fulfilled the needs of all organoleptic parameters and also the in vitro release study. These Ocusert will be surely an alternative for conventional eye drops and boon to patients in future.
Gemifloxacin Mesylate, Dexamethasone, Carbopol 974, 980, 981, Ocular inserts and Betacyclodextrin complex
